Escin B-containing pharmaceutical composition

A escin and composition technology, which is applied in the field of pharmacy, can solve problems such as difficulty in ensuring safety and unstable quality of aescin products, so as to reduce the phenomenon of stretching, reduce the degree of neurological deficit and mortality, and improve active effect

Active Publication Date: 2018-05-18
WUHAN AIMIN PHARMA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, high-purity aescin B can solve the current problems of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Escin B-containing pharmaceutical composition
  • Escin B-containing pharmaceutical composition
  • Escin B-containing pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] The present invention will be described in detail below by way of examples.

[0015] Test drug:

[0016] Composition injection: mix aescin B and niacin at a weight ratio of 10:1, 7:2, and 5:3 respectively, dissolve in water for injection, and prepare an injection containing 5 mg of aescin B per ml.

[0017] Aescin B injection: Dissolve aescin B in water for injection to make an injection containing 5 mg of aescin B per ml.

[0018] Niacin injection: Dissolve nicotinic acid in water for injection to make an injection containing 5 mg of nicotinic acid per ml.

[0019] 1. Establish a model of cerebral ischemia-reperfusion injury in rats: male SD rats, weighing 230-250 g, were anesthetized by intraperitoneal injection of 25% urethane solution, fixed on the operating table in a lateral position, and made a median incision in the neck to expose the common carotid artery , separate the internal carotid artery, clamp the common carotid artery and the internal carotid artery, slo

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating cerebral ischemic stroke, wherein the pharmaceutical composition comprises escin B or a sodium salt thereof, and nicotinic acid, and aweight ratio of the escin B or the sodium salt thereof to the nicotinic acid is 2-20:0.5-5. According to the present invention, the composition can reduce the neurological deficit degree and the mortality of cerebral ischemia-reperfusion injury animal models, reduce the infarct volume and the brain water content caused by cerebral ischemia, obviously increase the activity of SOD in the brain tissue of rats, reduce the generation of MDA, reduce the damage on cell membrane by free radicals, increase the activity of LDH in ischemic brain tissue, and reduce lactic acid accumulation, such that thepharmaceutical composition is the ideal drug for the treatment of cerebral ischemic stroke.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner WUHAN AIMIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap